© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
August 06, 2025
Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.
11 US Vaccine Policy Updates: How Will They Affect Your Practice?
August 06, 2025
Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.
Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD
August 06, 2025
The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.
Nearly 17 Million US Youth Found Eligible for GLP-1 RA Therapy and Most Because of Obesity
August 06, 2025
An NHANES-based cross sectional study found that 1 in 5 of the treatment-eligible youth lacked adequate insurance and one-third had no routine place for health care.
Primary Care Needs the Right Tools to Identify MCI Early, Says Rodney Swenson, PhD
August 06, 2025
If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.
The Biggest Threat to Vaccine Confidence in the US: An Expert Discussion
August 06, 2025
Amesh Adalja, MD, urges physicians to use their trusted position to counter widespread vaccine misinformation and strengthen patient confidence in immunization.
Cognition is The Next Vital Sign: An Interview with David J Libon, PhD
August 05, 2025
A cognitive health assessment will soon be as routine as taking blood pressure or pulse ox, says neurocognitive researcher David J Libon, PhD. He talks more about that future.
When Guidelines Diverge: Navigating Vaccine Recommendations in 2025
August 05, 2025
Amesh Adalja, MD, advises physicians turn to specialty societies for evidence-based, reliable recommendations this respiratory virus season.
Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain
August 05, 2025
The NaV1.8 ion channel inhibitor was planned as a follow-up to the company's first nonopioid for acute pain, suzetrigine, approved by the FDA in January 2025.